E-Newsletter - December 2023
Message From the Group Chair
 

Dear Alliance Researchers and Colleagues,

Please accept my deepest appreciation for everything you do everyday to change patients’ lives and create the medicine of the future.

I am truly inspired by our unique potential in Alliance: the engagement of our communities and diverse patient populations across the spectrum of clinical cancer research from prevention to treatment and cures; our track record in innovation and practice changing trials; our leadership in leveraging AI and EHR derived data to transform clinical trial conduct; the incredible talent among our investigators, advocates, and staff; and our investment in mentorship.

I believe that in Alliance, we are uniquely positioned to lead the way in reducing the impact of cancer. I am looking forward to a continued and dynamic partnership with all of you in the New Year and beyond to make this vision a reality.

Have a wonderful holiday season!

Evanthia Galanis, MD
Alliance Group Chair

 

 

Read other articles from this month's e-newsletter:

• Message From the Group Chair
• New Alliance Leadership Appointments
• 2023 Richard L. Schilsky CALGB Achievement Award
• Recently Activated Alliance Trials
• Ongoing Alliance Trials Now Enrolling Participants
• 2022-2023 Most Notable Alliance Publications
• Spotlight on Scientific Annual Meetings: 2023 SABCS & ASH
• In Memoriam: Worta J. McCaskill-Stevens, MD, MS - Founding Director, NCI Community Oncology Research Program (NCORP)
• Alliance Foundation Special Allocation Funding Opportunity
• Alliance/Alliance Entities Holiday Closures
• Alliance in the News
  :: Patients with HR-positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
  :: Can Irinotecan Boost Complete Response Rate and Long-term Organ Preservation in Rectal Cancer Patients?
  :: Sex-Associated Differences in Frequencies and Prognostic Impact of Recurrent Genetic Alterations in Adult Acute Myeloid Leukemia (Alliance, AMLCG)
  :: DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations
  :: ctDNA May Guide Treatment Intensity in RCC
  :: Quality of Life, Access Top Priorities in Cancer Care
  :: Dual-action Drug Produces Shows Promising Results In Neuroendocrine Tumor Trial
  :: Alliance for Clinical Trials in Oncology Study Shows Promise for Patients with Muscle-Invasive Urothelial Carcinoma
  :: Clinical Trial Shows Promising Results for Patients with Advanced Neuroendocrine Tumors
  :: Older, Hispanic Patients More Likely to Withdraw From Cancer Trials